TAp63^high CLL cases are resistant to the BCL2 inhibitor venetoclax. Bar graph illustrating the normalized viability (to DMSO-treated cells), measured by flow cytometry, in TAp63^high (n = 8) vs TAp63^low (n = 6) cases after 24 and 48 hours of venetoclax treatment. TAp63^high cases exhibit no statistically significant decrease in cell viability, whereas cell viability in TAp63^low cases was significantly reduced at both the 24-hour (A) and the 48-hour (B) timepoints. Because normalized viability is depicted in the graph, the value of each DMSO samples is equal to 1. **P ≤ .01. ABT-199, venetoclax.